HELEN HESLOP to Antiviral Agents
This is a "connection" page, showing publications HELEN HESLOP has written about Antiviral Agents.
Connection Strength
0.640
-
Pharmacotherapy versus T lymphocytes for CMV. Blood. 2013 May 02; 121(18):3544-5.
Score: 0.262
-
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
Score: 0.144
-
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
Score: 0.069
-
How I treat EBV lymphoproliferation. Blood. 2009 Nov 05; 114(19):4002-8.
Score: 0.051
-
Viral lymphomagenesis. Curr Opin Hematol. 2006 Jul; 13(4):254-9.
Score: 0.041
-
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330.
Score: 0.032
-
Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 Oct 15; 74(7):1050-2.
Score: 0.032
-
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8.
Score: 0.010